

Woodhead Publishing in Food Science and Technology

Functional dairy products

Volume 1

Edited by
Tiina Mattila-Sandholm and Maria Saarela



WOODHEAD PUBLISHING LIMITED

Contents

<i>List of contributors</i>	xi
-----------------------------------	----

1 Introduction: classifying functional dairy products 1

M. Saxelin, R. Korpela and A. Mäyrä-Mäkinen, Valio Ltd, Finland

1.1	Introduction	1
1.2	Composition of milk	1
1.3	Fermented milk products	2
1.4	What do we mean by functional dairy products?	5
1.5	Examples of functional dairy products: gastrointestinal health and general well-being	6
1.6	Examples of functional dairy products: cardiovascular health ...	10
1.7	Examples of functional dairy products: osteoporosis and other conditions	13
1.8	Future trends	14
1.9	Sources of further information and advice: links	15
1.10	References	15

Part I The health benefits of functional dairy products 17

2 Cancer 19

C. Gill and I. Rowland, University of Ulster, UK

2.1	Introduction	19
2.2	The relationship between diet and cancer	19
2.3	Colon carcinogenesis	21
2.4	Colorectal cancer and dairy products	23
2.5	Calcium	23
2.6	Casein	26
2.7	Whey	28

2.8	Conjugated linoleic acid	28
2.9	Sphingolipids	29
2.10	Prebiotics and probiotics	30
2.11	Mechanisms of anticarcinogenicity and antigenotoxicity for probiotics and prebiotics	41
2.12	Future trends	42
2.13	Sources of further information and advice	43
2.14	Acknowledgement	44
2.15	References	44
3	Coronary heart disease	54
	<i>J. Lovegrove and K. Jackson, The University of Reading, UK</i>	
3.1	Introduction	54
3.2	Risk factors in coronary heart disease	57
3.3	Relevant lipid particles	61
3.4	Diet and coronary heart disease	67
3.5	The effects of probiotics on coronary heart disease	74
3.6	The effects of prebiotics on coronary heart disease	80
3.7	The effects of synbiotics on coronary heart disease	85
3.8	Future trends	86
3.9	Sources of further information and advice	87
3.10	References	87
4	Osteoporosis	94
	<i>R. Wood, Tufts University, USA</i>	
4.1	Introduction	94
4.2	The epidemiology of osteoporosis	94
4.3	Dairy products, calcium intake and calcium absorption	98
4.4	Dairy products and osteoporosis	100
4.5	Future trends: genetic markers of osteoporosis risk	101
4.6	Future trends: redefining a nutritional prescription for optimal bone health	102
4.7	Sources of further information and advice	104
4.8	References	104
5	Probiotics and the management of food allergy	108
	<i>P. V. Kirjavainen, University of Turku, Finland</i>	
5.1	Introduction	108
5.2	The mechanisms and symptoms of food allergy	109
5.3	The prevalence of food allergy	113
5.4	Probiotics and food allergy: the clinical evidence	114
5.5	Mechanisms of action: gut microbiota composition and food allergies	116
5.6	Infant development and allergic sensitisation	119
5.7	Selecting the right probiotic	123
5.8	Conclusion and future trends	125

5.9	Sources of further information and advice	125
5.10	References	126
6	Dairy products and the immune function in the elderly	132
	<i>H. Gill, Massey University, Palmerston North, New Zealand</i>	
6.1	Introduction	132
6.2	The immune system	133
6.3	Immunosenescence	134
6.4	Nutrition and immune function in the elderly	137
6.5	Bovine milk and immunomodulation	139
6.6	Milk proteins	139
6.7	Antibodies and other protective agents in milk	145
6.8	Fermented dairy products and probiotic LAB	148
6.9	Immunomodulatory effects of fermented milk products and LAB	149
6.10	Future trends	157
6.11	References	158
7	The therapeutic use of probiotics in gastrointestinal inflammation ...	169
	<i>F. Shanahan, University College Cork, Ireland</i>	
7.1	Introduction	169
7.2	Bacteria in the gut	170
7.3	Studying gut flora	170
7.4	Gut flora and intestinal function	171
7.5	Gut immune function	173
7.6	Microbial subversion of intestinal immunosensory function ...	174
7.7	Bacterial translocation	174
7.8	Intestinal bacteria and IBD	175
7.9	Modifying the gut flora: probiotics in practice	177
7.10	Future trends	178
7.11	Sources of further information and advice	179
7.12	Acknowledgement	179
7.13	References	179
Part II	Functional dairy ingredients	185
8	Caseinophosphopeptides (CPPs) as functional ingredients	187
	<i>R.J. FitzGerald, University of Limerick, Ireland, and H. Meisel, Institut für Chemie und Technologie der Milch, Germany</i>	
8.1	Introduction	187
8.2	Structural characteristics and production of CPPs	188
8.3	CPPs and mineral (calcium) bioavailability	190
8.4	Human studies with CPPs	191
8.5	Effect of CPPs on mineral uptake in specific cell systems	192
8.6	Cytomodulatory effects	193

8.7	Safety assessment of CPPs	194
8.8	Potential ingredient applications of CPPs	195
8.9	Summary and future trends	197
8.10	References	198
9	Oligosaccharides	203
	<i>G. Boehm and B. Stahl, Numico Research Germany, Germany</i>	
9.1	Introduction	203
9.2	Structural aspects of free oligosaccharides	204
9.3	Physiological functions of dietary oligosaccharides	220
9.4	Effect on intestinal flora: prebiotic role	221
9.5	Effect on intestinal infections and mineral absorption	224
9.6	Effect on the immune system and other physiological effects ..	227
9.7	Analytical methods	228
9.8	Future trends	233
9.9	Acknowledgements	233
9.10	References	233
10	Lactic acid bacteria (LAB) in functional dairy products	244
	<i>R. Fondén, Arla Foods ICS, Sweden, M. Saarela, J. Mäntö and T. Mattila-Sandholm, VTT Biotechnology, Finland</i>	
10.1	Introduction	244
10.2	Production of dairy products using LAB	246
10.3	Dairy products with probiotic LAB	248
10.4	The health benefits of probiotic LAB	250
10.5	Enhancing the viability and stability of LAB	252
10.6	Enhancing the functionality of LAB	254
10.7	Future trends	256
10.8	Sources of further information and advice	257
10.9	References	257
11	Conjugated linoleic acid (CLA) as a functional ingredient	263
	<i>S. Gnädig, Y. Xue, O. Berdeaux, J.M. Chardigny and J-L. Sebedio, Institut National de la Recherche Agronomique, France</i>	
11.1	Introduction	263
11.2	Natural sources of CLA	263
11.3	Commercial production of CLA	267
11.4	Analytic methods	272
11.5	The influence of processing on the CLA content of dairy products	273
11.6	Functional benefits of CLA: cancer	274
11.7	Multisite anticarcinogenesis	275
11.8	Multistage anticarcinogenesis	277
11.9	Mechanisms of CLA anticarcinogenesis	278
11.10	Functional benefits of CLA: lipid and protein metabolism.	281

11.11	The process of CLA metabolism	284
11.12	Functional benefits of CLA: atherosclerosis	286
11.13	Functional benefits of CLA: immune function	287
11.14	Functional benefits of CLA: diabetes	288
11.15	Conclusion and future trends	289
11.16	References	289
Part III	Product development	299
12	Enhancing the functionality of prebiotics and probiotics	301
	<i>R. Rastall, The University of Reading, UK</i>	
12.1	Introduction	301
12.2	The functional enhancement of prebiotics	301
12.3	Targeted prebiotics	305
12.4	Current manufacturing technologies for prebiotics	307
12.5	Emerging manufacturing technologies for second generation prebiotics	309
12.6	The functional enhancement of probiotics	311
12.7	Conclusion and future trends	311
12.8	References	312
13	Safety evaluation of probiotics	316
	<i>A.C. Ouwehand and S. Salminen, University of Turku, Finland</i>	
13.1	Introduction	316
13.2	Key safety issues	317
13.3	Identifying probiotic strains	319
13.4	Potential risk factors: acute toxicity	320
13.5	Potential risk factors: microbial metabolism	320
13.6	Potential risk factors: microbial properties and binding	323
13.7	Other potential risk factors	325
13.8	Post-marketing surveillance	327
13.9	Safety issues for new generation probiotics	327
13.10	The safety of animal probiotics	328
13.11	The current regulatory context	329
13.12	Conclusion and future trends	331
13.13	Sources for further information and advice	332
13.14	References	332
14	Clinical trials	337
	<i>P. Marteau, Paris V University, France</i>	
14.1	Introduction	337
14.2	Setting up a clinical trial: protocols	337
14.3	Statistical analysis	340
14.4	Ethical issues	341
14.5	Managing a clinical trial	343

14.6	Assessing the validity of a clinical trial	343
14.7	Sources of further information and advice	344
14.8	References	344
15	Consumers and functional foods	346
	<i>L. Lähteenmäki, VTT Biotechnology, Finland</i>	
15.1	Functional foods and consumers	346
15.2	The role of health in food choice	347
15.3	Nutritional guidelines and health claims	349
15.4	Consumers, claims and carrier products	350
15.5	Consumer attitudes to functional foods	354
15.6	Future trends	356
15.7	Sources of further information and advice	357
15.8	References	357
16	European research in probiotics and prebiotics: the PROEUHEALTH cluster	359
	<i>T. Mattila-Sandholm, L. Lähteenmäki and M. Saarela, VTT Biotechnology, Finland</i>	
16.1	Introduction: research projects within the PROEUHEALTH cluster	359
16.2	Developing research tools: MICROBE DIAGNOSTICS	364
16.3	Understanding mechanisms of actions: DEPROHEALTH, PROPATH and EU MICROFUNCTION	365
16.4	Investigating effects on health: PROGID, CROWNALIFE and PROSAFE	368
16.5	Probiotic and prebiotic technologies: PROTECH	371
16.6	Consumers and the perceived health benefits of probiotics	372
16.7	Conclusions and future trends	374
16.8	References	375
17	The market for functional dairy products: the case of the United States	378
	<i>L. Hoolihan, Dairy Council of California, USA</i>	
17.1	Introduction	378
17.2	Drivers of the functional foods market	379
17.3	The growth of the functional foods market in the US	380
17.4	The regulatory context in the US	381
17.5	The potential for functional dairy foods in the US	384
17.6	Future trends	386
17.7	Sources of further information and advice	388
17.8	References	388
	<i>Index</i>	390